Enterprise pivot reinforces Similarweb's potential buy thesis; fundamentals still need to confirm

What happened

Similarweb's strategic shift towards enterprise customers is gaining traction, as a Seeking Alpha article reiterates a buy rating and notes that the stock's ~5% YTD gain does not yet reflect growing pipeline and deal momentum. The article highlights improving fundamentals, larger deal signings, and an emerging margin profile as catalysts for a rerating. This aligns with our DeepValue master report's 'Potential Buy' rating, which values the stock at $9 in the base case, supported by 58% of ARR on multi-year contracts and 63% of ARR from customers spending over $100k annually. Recent data shows revenue growth of 11% YoY in Q3 2025, with NRR at 98% overall, a key watchpoint that could temper optimism. While the enterprise push is promising, no new financial data was provided, so we continue to monitor execution rather than change our thesis.

Implication

For investors, the enterprise push described in the article is consistent with our base case, but it remains anecdotal until reflected in sustained NRR above 100% and larger deal contributions. We would not add to positions solely based on this commentary; instead, we require confirmation from Q4 2025 results and 2026 guidance, particularly regarding net revenue retention and free cash flow margin. The stock's current valuation at ~1.7x forward revenue leaves room for upside if management delivers on mid-teens growth and margin expansion, but downside risk persists if enterprise churn increases. We continue to see attractive entry around $5, with a trim level near $10, and we will reassess if NRR stays below 100% for two consecutive quarters or FCF turns negative. Overall, maintain a measured position, focusing on execution metrics rather than promotional narratives.

Thesis delta

No material change to our investment thesis. The article reinforces our view that enterprise customers are increasingly adopting Similarweb, but it offers no new quantitative evidence to adjust our probability-weighted valuation. Consequently, our 'Potential Buy' rating and $9 base-case value remain unchanged, with conviction unchanged at 3.5.